News
PTHS
27.00
+3.25%
0.85
Pelthos Therapeutics Earnings Call Shows Strong Launch
TipRanks · 23h ago
Analysts Offer Insights on Healthcare Companies: BioCardia (BCDA), Pelthos Therapeutics (PTHS) and Airsculpt Technologies (AIRS)
TipRanks · 1d ago
Weekly Report: what happened at PTHS last week (0511-0515)?
Weekly Report · 1d ago
Pelthos Therapeutics Q1 Earnings Call Highlights
Barchart · 4d ago
Roth MKM Remains a Buy on Pelthos Therapeutics (PTHS)
TipRanks · 4d ago
Pelthos Therapeutics Is Maintained at Outperform by Oppenheimer
Dow Jones · 4d ago
Oppenheimer Maintains Outperform on Pelthos Therapeutics, Raises Price Target to $66
Benzinga · 4d ago
Lake Street Reaffirms Their Buy Rating on Pelthos Therapeutics (PTHS)
TipRanks · 4d ago
Pelthos Therapeutics price target raised to $66 from $62 at Oppenheimer
TipRanks · 4d ago
H.C. Wainwright Remains a Buy on Pelthos Therapeutics (PTHS)
TipRanks · 4d ago
Pelthos outlines mid-2027 XEGLYZE launch timing as ZELSUVMI Q1 net product revenue reaches $10.7M
Seeking Alpha · 5d ago
Analysts Offer Insights on Healthcare Companies: Keros Therapeutics (KROS) and Pelthos Therapeutics (PTHS)
TipRanks · 5d ago
Pelthos Therapeutics GAAP EPS of -$3.09, revenue of $10.7M
Seeking Alpha · 5d ago
Pelthos Therapeutics Q1 2026 Earnings Call Transcript
Benzinga · 5d ago
Pelthos Therapeutics reports Q1 EPS ($3.58), consensus ($3.09)
TipRanks · 5d ago
Pelthos Therapeutics Reports Strong Q1 Growth for ZELSUVMI
TipRanks · 5d ago
Earnings Scheduled For May 14, 2026
Benzinga · 5d ago
Pelthos Therapeutics Q1 EPS $(3.09) Beats $(3.81) Estimate, Sales $10.906M Beat $10.445M Estimate
Benzinga · 5d ago
*Pelthos Therapeutics 4Q Rev $10.9M >PTHS
Dow Jones · 5d ago
Press Release: Pelthos Therapeutics Announces -3-
Dow Jones · 5d ago
More
Webull provides a variety of real-time PTHS stock news. You can receive the latest news about Pelthos Therapeutics through multiple platforms. This information may help you make smarter investment decisions.
About PTHS
Pelthos Therapeutics Inc. is a biopharmaceutical company focused on commercializing therapeutic products for unmet patient needs. The Company's lead product, ZELSUVMI (berdazimer) topical gel, 10.3%, is used in the treatment of molluscum contagiosum infections (molluscum) in adults and pediatric patients one year of age and older. In addition to ZELSUVMI, the Company has a pipeline of product candidates that utilize its proprietary nitric oxide-based technology platform, NITRICIL. The Company’s product Xepi is a quinolone antimicrobial indicated for the topical treatment of impetigo due to Staphylococcus aureus or Streptococcus pyogenes in adult and pediatric patients two months of age and older. Its NaV 1.7 is a clinical-stage assets which selectively target the sodium ion-channel. The Company also Xeglyze, which is a is a pediculicide indicated for the topical treatment of head lice infestation in patients six months of age and older.